Mostrando 10 resultados de: 14
Filtros aplicados
Publisher
Elsevier(5)
AMER ASSOC BLOOD BANKS(1)
American Society for Microbiology Journals(1)
Taylor & Francis(1)
Universidad Central del Ecuador(1)
Área temáticas
Enfermedades(9)
Medicina forense; incidencia de enfermedades(7)
Ganadería(5)
Microorganismos, hongos y algas(5)
Farmacología y terapéutica(4)
Área de conocimiento
Medicina veterinaria(5)
Epidemiología(2)
Inmunología(2)
Microbiología(2)
Salud pública(2)
A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN)
OtherAbstract: Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleConhecimento, Percepções de Indivíduos em Relação à Leishmaniose Visceral Humana Como Novas Ferramentas de Controle Knowledge, Perceptions of Individuals Regarding to Human …
OtherAbstract: O Brasil sofre atualmente um sério problema de saúde pública quanto à leishmaniose visceral humana (Palabras claves:Autores:Gulnara Borja-CabreraFuentes:googleCross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis
OtherAbstract: The fucose-mannose ligand (FML) complex of Leishmania donovani is a promising vaccine candidate agaiPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleEstudio de factores de riesgo para transmisión de leishmaniosis cutánea americana en una área endémica de la Provincia de Pichincha
ArticleAbstract: Contexto: En Ecuador, la leishmaniosis cutánea americana se reporta en 20 de 22 provincias, con unaPalabras claves:ACTITUDES, attitudes, conocimientos, Cutaneous leishmaniasis, epidemiology, epiolemiología, FACTORES DE RIESGO, knowledge, Leishmaniosis cutánea, PICHINCHA, PRACTICAS, practices, RISK FACTORSAutores:Bryan Suárez, Gabriela Robles, Gulnara Borja-Cabrera, Jessica Gómez, Jorge Quinchuela, Jorge Tufiño, Soraya RiveraFuentes:googlerraaeFML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine
OtherAbstract: The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical andPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleImmunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine
OtherAbstract: In order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the LeishmunePalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleKinetic studies and evaluation of potential compounds for the chemotherapy of Leishmaniasis using LdNH-MBP
OtherAbstract: Full text: Protozoan parasites rely exclusively on purine salvage from the host for DNA and RNA syntPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleThe FML-vaccine (Leishmune®) against canine visceral leishmaniasis: a transmission blocking vaccine
OtherAbstract: Transmission blocking vaccines are one of the control strategies for vector-transmitted protozoan diPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleThe Outcome of Multibacillary Patients infected with Mycobacterium leprae treated with Multidrug Therapy associated with the Biotherapic Tuberculinum 30 CH
OtherAbstract: 1-Master of Biological Sciences, University Vale do Rio Doce, Governador Valadares, Brazil. 2-PharmBPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleOccurrence of Leishmania donovani DNA in bone marrow of FML-seroreactive Brazilian blood donors.
OtherAbstract:Palabras claves:Autores:Gulnara Borja-CabreraFuentes:google